Home › NDC Lookup › RxCUI directory › RxCUI 197894

Lomustine 10 MG Oral Capsule — RxCUI 197894

RxNorm drug concept · Semantic clinical drug
RxCUI 197894 Semantic clinical drug · SCD ● Current RxNorm concept 12 FDA products 12 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197894
Official nameLomustine 10 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped12
Package NDCs mapped12
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lomustine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • That 6-week gap is actually a critical safety feature, not just a scheduling choice. Lomustine causes a delayed drop in your blood cell counts — typically peaking about 4 to 6 week...
  • Why do I only take this pill once every 6 weeks? That seems like a long time between doses.
  • Yes, that's completely intentional and a strict safety rule. Your pharmacist is only allowed to dispense exactly enough capsules for one dose at a time. Taking more than one dose's...
  • My pharmacy only gave me a few capsules — is that normal? Shouldn't I have a full bottle?
📖 Read our full Lomustine guide →

🕸️ Concept Web — How Lomustine 10 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Lomustine 10 MG Oral Capsule RxCUI 197894

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Lomustine 6466
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Gleostine 1545771
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Lomustine Oral Capsule 372631
    • Lomustine Oral Product 1165319
    • Lomustine Pill 1165320
    • Lomustine Oral Capsule [Gleostine] 1545773
    • Gleostine Oral Product 1545774
    • Gleostine Pill 1545775
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Lomustine 10 MG SCDC · 316160
  • Lomustine Oral Capsule SCDF · 372631
  • Lomustine Oral Product SCDG · 1165319
  • Lomustine Pill SCDG · 1165320

Brand-Name Concepts

  • Lomustine 10 MG Oral Capsule [Gleostine] SBD · 1545776
  • Lomustine 10 MG [Gleostine] SBDC · 1545772
  • Lomustine Oral Capsule [Gleostine] SBDF · 1545773
  • Gleostine Oral Product SBDG · 1545774
  • Gleostine Pill SBDG · 1545775
  • Gleostine BN · 1545771

📦 FDA Products & Package NDCs

12 products · 12 package NDCs
12 package NDCs map to RxCUI 197894 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
24338-0340-05 1 BOTTLE in 1 CARTON (24338-340-05) / 5 CAPSULE, GELATIN CO... Gleostine Azurity Pharmaceuticals, Inc. 2025-10-24
24338-0341-05 1 BOTTLE in 1 CARTON (24338-341-05) / 5 CAPSULE, GELATIN CO... Gleostine Azurity Pharmaceuticals, Inc. 2025-10-24
24338-0342-05 1 BOTTLE in 1 CARTON (24338-342-05) / 5 CAPSULE, GELATIN CO... Gleostine Azurity Pharmaceuticals, Inc. 2025-10-24
52536-0340-05 1 BOTTLE in 1 CARTON (52536-340-05) / 5 CAPSULE, GELATIN CO... Lomustine Wilshire Pharmaceuticals, Inc. 2026-04-15
52536-0341-05 1 BOTTLE in 1 CARTON (52536-341-05) / 5 CAPSULE, GELATIN CO... Lomustine Wilshire Pharmaceuticals, Inc. 2026-04-15
52536-0342-05 1 BOTTLE in 1 CARTON (52536-342-05) / 5 CAPSULE, GELATIN CO... Lomustine Wilshire Pharmaceuticals, Inc. 2026-04-15
58181-3040-05 1 BOTTLE in 1 CARTON (58181-3040-5) / 5 CAPSULE, GELATIN CO... Gleostine NextSource Biotechnology, LLC 2014-08-18
58181-3041-05 1 BOTTLE in 1 CARTON (58181-3041-5) / 5 CAPSULE, GELATIN CO... Gleostine NextSource Biotechnology, LLC 2014-08-18
58181-3042-05 1 BOTTLE in 1 CARTON (58181-3042-5) / 5 CAPSULE, GELATIN CO... Gleostine NextSource Biotechnology, LLC 2014-08-18
80005-0114-02 5 CAPSULE in 1 BOTTLE (80005-114-02) LOMUSTINE Carnegie Pharmaceuticals LLC 2025-11-10
80005-0115-02 5 CAPSULE in 1 BOTTLE (80005-115-02) LOMUSTINE Carnegie Pharmaceuticals LLC 2025-11-10
80005-0116-02 5 CAPSULE in 1 BOTTLE (80005-116-02) LOMUSTINE Carnegie Pharmaceuticals LLC 2025-11-10
Observed labelers: Azurity Pharmaceuticals, Inc. (3) · Carnegie Pharmaceuticals LLC (3) · NextSource Biotechnology, LLC (3) · Wilshire Pharmaceuticals, Inc. (3) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.